Work

Figure 6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Year: 2023
Type: other
Abstract: Birinapant potentiates the antitumoral effect of ER blockade. A, Cell growth studies of MCF7 cells treated with vehicle (DMSO), fulvestrant, birinapant, and the combination of fulvestrant and birinapant for 7 days. The number of cells were measured at days 0, 3, 5, and 7. Error bars, SD from four replicates. B, Synergy study of the combination of fulvestrant and birinapant MCF7 cells. Synergy was calculated based on the ZIP reference model using SynergyFinder (www.synergyfinder.org). Deviations between observed and expected responses with positive and negative values denote synergy and antagonism, respectively. C, ER+/HER2− PDX tumor growth study. Error bars, SD (N = 5 mice per group). D, GSEA of genes differentially expressed in MCF7 cells after treatment with fulvestrant (10 nmol/L), birinapant (100 nmol/L), or the combination compared with vehicle (DMSO) control. The size of each circle indicates the q value (genes sets with a q value of <0.25 in at least one condition were included); the color scale indicates the normalized enrichment score (NES). *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-way Anova.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4387262909
Cites:
Cited by:
Related to: 10